The spin-off from the University at Buffalo Cytocybernetics  has received $1.5 million from the National Institute of Health (NIH) to develop their study of the heart’s electoral activity when introduced to new medication. The hope is to create an enhanced version of the current device, Cybercyte, which integrates electronics with heart muscle cells to see how they react to new drugs. 
The Cybercyte is a tool which allows experts to use a dynamic clamp, or the electrophysiology method that is able to connect one or several living cells with a computer in order to simulate dynamic processes , in any lab situation. This gives researchers and medical professionals access to important information when it comes to understanding reactions within the body. 
An advanced version of this tool could change the way pharmaceutical companies identify how new medicines affects the heart muscle, providing them with instant or almost instant feedback of how their new products work. For a company that is constantly testing different types of drugs, this technology could save millions of dollars and lives.